We hypothesized that perturbational drug signatures in the CMap database that are statistically “connected” to (i.e., significantly correlated with) the unique gene signature of FOXM1 deficiency in myeloma may nominate drug candidates that mimic the genetic loss of FOXM1 in myeloma. This evidence concerns the gene FOXM1 and plasma cell myeloma.